|
US20040028686A1
(en)
*
|
2001-06-28 |
2004-02-12 |
Faulk Ward Page |
Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplated organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
PT1392359E
(pt)
|
2001-05-11 |
2010-01-27 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
|
US7129261B2
(en)
|
2001-05-31 |
2006-10-31 |
Medarex, Inc. |
Cytotoxic agents
|
|
US20060198882A1
(en)
*
|
2003-03-21 |
2006-09-07 |
Yechezkel Barenholz |
Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
|
|
EP2281577B1
(en)
|
2003-05-14 |
2016-11-16 |
ImmunoGen, Inc. |
Drug conjugate composition
|
|
WO2005042002A2
(en)
*
|
2003-10-30 |
2005-05-12 |
Entelos, Inc. |
Treatment of rhematoid arthritis with flip antagonists
|
|
US20070287680A1
(en)
*
|
2004-05-10 |
2007-12-13 |
University Of Utah Research Foundation |
Combined Active and Passive Targeting of Biologically Active Agents
|
|
CA2564076C
(en)
|
2004-05-19 |
2014-02-18 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
EP1817004A2
(en)
*
|
2004-11-15 |
2007-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
|
EP2468304A3
(en)
|
2005-02-11 |
2012-09-26 |
ImmunoGen, Inc. |
Process for preparing stable drug conjugates
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
JP2009503105A
(ja)
|
2005-08-03 |
2009-01-29 |
イミュノジェン・インコーポレーテッド |
免疫複合体製剤
|
|
CA2893252C
(en)
|
2005-08-24 |
2018-05-29 |
Immunogen, Inc. |
Process for preparing antibody maytansinoid conjugates
|
|
EA016577B1
(ru)
*
|
2005-09-26 |
2012-06-29 |
Медарекс, Инк. |
Конъюгаты антитело-лекарство и их применение
|
|
SI1940789T1
(sl)
|
2005-10-26 |
2012-03-30 |
Medarex Inc |
Postopki in spojine za pripravo cc analogov
|
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
WO2008010101A2
(en)
|
2006-07-18 |
2008-01-24 |
Sanofi-Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
MX338185B
(es)
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
|
WO2008103693A2
(en)
|
2007-02-21 |
2008-08-28 |
Medarex, Inc. |
Chemical linkers with single amino acids and conjugates thereof
|
|
AU2008227123B2
(en)
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
|
PE20090499A1
(es)
|
2007-08-09 |
2009-05-18 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
|
|
ES2566957T3
(es)
|
2007-09-26 |
2016-04-18 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
US8742076B2
(en)
*
|
2008-02-01 |
2014-06-03 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
|
FR2933702A1
(fr)
*
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
ES2532635T3
(es)
|
2008-07-15 |
2015-03-30 |
Genentech, Inc. |
Conjugados de antraciclina, proceso para su preparación y su uso como compuestos antitumorales
|
|
CN102365297B
(zh)
|
2009-03-25 |
2014-10-29 |
霍夫曼-拉罗奇有限公司 |
新型抗-α5β1抗体及其应用
|
|
KR102444399B1
(ko)
|
2009-06-03 |
2022-09-16 |
이뮤노젠 아이엔씨 |
메이탄시노이드의 제조방법
|
|
CA2781519A1
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
|
EP2486023A4
(en)
|
2009-10-06 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
|
HUE044179T2
(hu)
|
2009-12-10 |
2019-10-28 |
Hoffmann La Roche |
Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása
|
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
|
EP2542588A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
BR112012027995A2
(pt)
|
2010-06-18 |
2017-01-10 |
Genentech Inc |
anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
|
CN103168049B
(zh)
|
2010-08-13 |
2015-10-07 |
罗切格利卡特公司 |
抗生腱蛋白-c a2抗体及使用方法
|
|
JP2013537539A
(ja)
|
2010-08-13 |
2013-10-03 |
ジェネンテック， インコーポレイテッド |
疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
|
|
KR101780131B1
(ko)
|
2010-08-13 |
2017-09-19 |
로슈 글리카트 아게 |
항-fap 항체 및 이의 사용 방법
|
|
RU2013114360A
(ru)
|
2010-08-31 |
2014-10-10 |
Дженентек, Инк. |
Биомаркеры и способы лечения
|
|
EP3176184B1
(en)
|
2010-11-10 |
2020-02-19 |
F. Hoffmann-La Roche AG |
Anti-bace1 antibodies for neural disease immunotherapy
|
|
RU2563638C2
(ru)
|
2010-12-02 |
2015-09-20 |
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. |
Способ получения производных морфолинилантрациклина
|
|
TWI732259B
(zh)
|
2010-12-16 |
2021-07-01 |
美商建南德克公司 |
關於th2抑制作用之診斷及治療
|
|
WO2012087962A2
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
SG191219A1
(en)
|
2010-12-22 |
2013-07-31 |
Genentech Inc |
Anti-pcsk9 antibodies and methods of use
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
CN107537040A
(zh)
|
2011-03-29 |
2018-01-05 |
伊缪诺金公司 |
通过一步法制备类美登素抗体缀合物
|
|
SG193996A1
(en)
|
2011-03-29 |
2013-11-29 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
KR101614195B1
(ko)
|
2011-03-29 |
2016-04-20 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
|
RU2013150331A
(ru)
|
2011-04-20 |
2015-05-27 |
Рош Гликарт Аг |
СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
|
|
BR112013026266A2
(pt)
|
2011-05-16 |
2020-11-10 |
Genentech, Inc |
método de tratamento, anticorpos isolado e anti-fgfr1, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de diabetes em um indivíduo
|
|
KR102087854B1
(ko)
|
2011-06-10 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-중합체-약물 접합체
|
|
KR20140045440A
(ko)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
항-c-met 항체 제제
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
KR101723273B1
(ko)
|
2011-08-23 |
2017-04-04 |
로슈 글리카트 아게 |
2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
|
|
CA2844540C
(en)
|
2011-08-23 |
2018-10-16 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
JP2014534949A
(ja)
|
2011-09-19 |
2014-12-25 |
ジェネンテック， インコーポレイテッド |
Ｃ−ｍｅｔアンタゴニストおよびｂ−ｒａｆアンタゴニストを含む組合せ処置
|
|
WO2013041462A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Glycart Ag |
Bispecific anti-egfr/anti igf-1r antibodies
|
|
WO2013052155A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
|
WO2013056054A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc |
Peptide inhibitors of bace1
|
|
HUE039133T2
(hu)
|
2011-10-14 |
2018-12-28 |
Hoffmann La Roche |
Anti-HtrA1 antitestek és felhasználási módszerek
|
|
EP2766000A2
(en)
|
2011-10-15 |
2014-08-20 |
F.Hoffmann-La Roche Ag |
Scd1 antagonists for treating cancer
|
|
AU2012328980A1
(en)
|
2011-10-28 |
2014-04-24 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
|
BR112014012624A2
(pt)
|
2011-12-15 |
2018-10-09 |
F Hoffmann-La Roche Ag |
anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
|
|
EP2804629A1
(en)
|
2012-01-18 |
2014-11-26 |
Genentech, Inc. |
Anti-lrp5 antibodies and methods of use
|
|
US20130183294A1
(en)
|
2012-01-18 |
2013-07-18 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
|
EP2812357B1
(en)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Single-chain antibodies and other heteromultimers
|
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
|
CN104125852B9
(zh)
|
2012-02-15 |
2017-05-17 |
弗·哈夫曼-拉罗切有限公司 |
基于Fc‑受体的亲和色谱
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
JP2015516980A
(ja)
|
2012-04-26 |
2015-06-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体とベンダムスチンとの併用
|
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
WO2013171287A1
(en)
|
2012-05-16 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
|
|
EP2849783A1
(en)
|
2012-05-16 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Combination of cd37 antibodies with further agents
|
|
ES2703540T3
(es)
|
2012-06-04 |
2019-03-11 |
Novartis Ag |
Métodos de marcación específicos del sitio y moléculas producidas de este modo
|
|
WO2013188855A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
WO2014001326A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
RU2630664C2
(ru)
|
2012-07-04 |
2017-09-11 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к теофиллину и способы их применения
|
|
WO2014006123A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
|
ES2604012T3
(es)
|
2012-07-04 |
2017-03-02 |
F. Hoffmann-La Roche Ag |
Conjugados de antígeno-anticuerpo unidos covalentemente
|
|
TW201408696A
(zh)
|
2012-07-09 |
2014-03-01 |
Genentech Inc |
抗ｃｄ２２抗體及免疫結合物
|
|
US20140030282A1
(en)
|
2012-07-09 |
2014-01-30 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates
|
|
SMT202100621T1
(it)
|
2012-07-13 |
2022-01-10 |
Roche Glycart Ag |
Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
|
|
SG11201502429YA
(en)
|
2012-10-04 |
2015-04-29 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
|
MA38176A1
(fr)
|
2012-11-13 |
2017-06-30 |
Genentech Inc |
Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
|
|
JP6133431B2
(ja)
|
2012-11-24 |
2017-05-24 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
MX2015010146A
(es)
|
2013-02-08 |
2016-05-31 |
Novartis Ag |
Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
|
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
|
EP2961772A1
(en)
|
2013-02-26 |
2016-01-06 |
Roche Glycart AG |
Anti-mcsp antibodies
|
|
WO2014138364A2
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2014153030A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
AU2014236815B2
(en)
|
2013-03-15 |
2019-04-04 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
JP2016517441A
(ja)
|
2013-03-15 |
2016-06-16 |
ジェネンテック， インコーポレイテッド |
抗ＣＲＴｈ２抗体及び使用方法
|
|
AU2014235453A1
(en)
|
2013-03-15 |
2015-10-08 |
Genentech, Inc. |
Biomarkers and methods of treating PD-1 and PD-L1 related conditions
|
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
JP6333943B2
(ja)
|
2013-03-15 |
2018-05-30 |
ノバルティス アーゲー |
抗体薬物コンジュゲート
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
CN118561989A
(zh)
|
2013-04-29 |
2024-08-30 |
豪夫迈·罗氏有限公司 |
Fc-受体结合的修饰的非对称抗体及使用方法
|
|
PL3594240T3
(pl)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
JP2016537399A
(ja)
|
2013-09-17 |
2016-12-01 |
ジェネンテック， インコーポレイテッド |
抗ｌｇｒ５抗体を使用する方法
|
|
KR102087850B1
(ko)
|
2013-10-11 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-고분자-약물 접합체
|
|
US10316080B2
(en)
|
2013-10-11 |
2019-06-11 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
WO2015095223A2
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
JP6521464B2
(ja)
|
2014-01-03 |
2019-05-29 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
共有結合で連結されたポリペプチド毒素−抗体コンジュゲート
|
|
KR102278979B1
(ko)
|
2014-01-03 |
2021-07-19 |
에프. 호프만-라 로슈 아게 |
공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
|
|
US10561737B2
(en)
|
2014-01-03 |
2020-02-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
EA201691610A8
(ru)
|
2014-02-12 |
2018-05-31 |
Дженентек, Инк. |
Анти-jagged1 антитела и способы применения
|
|
CR20160379A
(es)
|
2014-02-21 |
2016-10-07 |
Genentech Inc |
Anticuerpos biespecificos anti-il 13/il-17 y sus usos
|
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
|
AU2015229463A1
(en)
|
2014-03-12 |
2016-09-15 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
AU2015229035B2
(en)
|
2014-03-14 |
2021-08-05 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
CN106103478B
(zh)
|
2014-03-21 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
抗体体内半寿期的体外预测
|
|
WO2015148531A1
(en)
|
2014-03-24 |
2015-10-01 |
Genentech, Inc. |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
EP3126394B1
(en)
|
2014-03-31 |
2019-10-30 |
F.Hoffmann-La Roche Ag |
Anti-ox40 antibodies and methods of use
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
|
CN106661622B
(zh)
|
2014-05-23 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
Mit生物标志物和使用它们的方法
|
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
MX384037B
(es)
|
2014-06-26 |
2025-03-14 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
|
RU2017103289A
(ru)
|
2014-07-11 |
2018-08-14 |
Дженентек, Инк. |
Ингибирование пути notch
|
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
|
BR112017001588A2
(pt)
|
2014-08-12 |
2017-11-21 |
Novartis Ag |
conjugados de anticorpo/fármaco anti-cdh6
|
|
MX2017002605A
(es)
|
2014-08-28 |
2017-05-19 |
Bioatla Llc |
Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
PE20170935A1
(es)
|
2014-09-12 |
2017-07-13 |
Genentech Inc |
Anticuerpos anti-her2 e inmunoconjugados
|
|
BR112017004802A2
(pt)
|
2014-09-12 |
2017-12-12 |
Genentech Inc |
anticorpos anti-cll-1 e imunoconjugados
|
|
WO2016040825A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
|
WO2016061389A2
(en)
|
2014-10-16 |
2016-04-21 |
Genentech, Inc. |
Anti-alpha-synuclein antibodies and methods of use
|
|
CN107148283A
(zh)
|
2014-10-31 |
2017-09-08 |
豪夫迈·罗氏有限公司 |
抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
|
|
EP3215637B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment
|
|
MX2017005750A
(es)
|
2014-11-03 |
2017-12-15 |
Genentech Inc |
Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso.
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
RU2714116C2
(ru)
|
2014-11-06 |
2020-02-11 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
BR112017009728A2
(pt)
|
2014-11-10 |
2018-02-06 |
Genentech, Inc. |
anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
|
|
AU2015347015B2
(en)
|
2014-11-14 |
2019-02-14 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
US10882920B2
(en)
|
2014-11-19 |
2021-01-05 |
Genentech, Inc. |
Antibodies against BACE1 and use thereof for neural disease immunotherapy
|
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
PT3227336T
(pt)
|
2014-12-05 |
2019-09-09 |
Hoffmann La Roche |
Anticorpos anti-cd79b e métodos de utilização
|
|
CN107207591A
(zh)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
血脑屏障受体抗体及使用方法
|
|
JP6227191B1
(ja)
|
2014-12-19 |
2017-11-08 |
中外製薬株式会社 |
抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
|
|
US9765135B2
(en)
|
2014-12-19 |
2017-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies
|
|
CA2973964A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
CN114773470A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
|
HK1252158A1
(zh)
|
2015-05-01 |
2019-05-17 |
Genentech, Inc. |
掩蔽抗cd3抗体和使用方法
|
|
EP3294771A1
(en)
|
2015-05-11 |
2018-03-21 |
H. Hoffnabb-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
|
HRP20201900T4
(hr)
|
2015-05-12 |
2024-06-07 |
F. Hoffmann - La Roche Ag |
Terapeutski i dijagnostički postupci kod raka
|
|
HK1250723A1
(zh)
|
2015-05-29 |
2019-01-11 |
F. Hoffmann-La Roche Ag |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
CA2985483A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
|
HUE063270T2
(hu)
|
2015-06-16 |
2024-01-28 |
Hoffmann La Roche |
Az FcRH5 elleni humanizált és affinitásérett antitestek és alkalmazási eljárások
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
DK3313879T3
(da)
|
2015-06-24 |
2022-03-14 |
Hoffmann La Roche |
Anti-transferrinreceptor-antistoffer med tilpasset affinitet
|
|
WO2016207091A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
|
|
US20170029520A1
(en)
|
2015-06-29 |
2017-02-02 |
Genentech, Inc. |
Compositions and methods for use in organ transplantation
|
|
EP3319936B1
(en)
|
2015-07-12 |
2025-12-17 |
Hangzhou Dac Biotech Co., Ltd. |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
MX2018001522A
(es)
|
2015-08-05 |
2018-03-15 |
Janssen Biotech Inc |
Anticuerpos anti-cd154 y metodos de uso de estos.
|
|
US10509035B2
(en)
|
2015-08-07 |
2019-12-17 |
Gamamabs Pharma Sa |
Antibodies, antibody drug conjugates and methods of use
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
CA2992602A1
(en)
|
2015-09-23 |
2017-03-30 |
Genentech, Inc. |
Optimized variants of anti-vegf antibodies
|
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
|
NZ739750A
(en)
|
2015-09-25 |
2019-11-29 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
BR112018006360A2
(pt)
|
2015-09-30 |
2018-10-09 |
Janssen Biotech Inc |
anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
|
|
MY192202A
(en)
|
2015-10-02 |
2022-08-06 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
|
KR102072317B1
(ko)
|
2015-10-02 |
2020-01-31 |
에프. 호프만-라 로슈 아게 |
항-pd1 항체 및 사용 방법
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
EP3356406A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
EP3368579B1
(en)
|
2015-10-30 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Hinge modified antibody fragments and methods of making
|
|
LT3370768T
(lt)
|
2015-11-03 |
2022-05-25 |
Janssen Biotech, Inc. |
Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
|
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
WO2017100402A1
(en)
*
|
2015-12-11 |
2017-06-15 |
Archer Daniels Midland Company |
One-pot synthesis of anhydropentitol esters from pentitols, catalyzed by water-tolerant lewis acids
|
|
SG10201707267RA
(en)
|
2015-12-18 |
2017-10-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
SI3390442T1
(sl)
|
2015-12-18 |
2024-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
Protitelesa proti c5 in postopki uporabe
|
|
KR20180119632A
(ko)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
MX395074B
(es)
|
2016-04-15 |
2025-03-24 |
Bioatla Llc |
Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos
|
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
AU2017259869A1
(en)
|
2016-05-02 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
The contorsbody - a single chain target binder
|
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
|
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
|
PL3455261T3
(pl)
|
2016-05-13 |
2022-12-12 |
Bioatla, Inc. |
Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
|
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック， インコーポレイテッド |
部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
MX2018014375A
(es)
|
2016-06-17 |
2019-04-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y metodos de uso.
|
|
CN109310765A
(zh)
*
|
2016-06-20 |
2019-02-05 |
领先基因生物技术股份有限公司 |
抗体-药物偶联物
|
|
BR112019001327A2
(pt)
|
2016-07-29 |
2019-04-30 |
Juno Therapeutics Inc |
anticorpos anti-idiotípicos e métodos relacionados
|
|
IL264626B
(en)
|
2016-08-05 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Composition for prophylaxis or treatment of il-8 related diseases
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
CN109790220A
(zh)
|
2016-08-25 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
|
JP7579056B2
(ja)
|
2016-10-06 |
2024-11-07 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
|
KR20220147721A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
CA3042435A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
JP7313684B2
(ja)
|
2016-11-21 |
2023-07-25 |
キュレアブ ゲーエムベーハー |
抗ｇｐ７３抗体及びイムノコンジュゲート
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
EP3558360A1
(en)
|
2016-12-22 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
|
SG10202107429WA
(en)
|
2017-01-06 |
2021-08-30 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
US10738131B2
(en)
|
2017-02-10 |
2020-08-11 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
MX2019012793A
(es)
|
2017-04-27 |
2020-02-13 |
Tesaro Inc |
Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3630829A1
(en)
|
2017-06-02 |
2020-04-08 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
JP7320458B2
(ja)
|
2017-06-22 |
2023-08-03 |
メルサナ セラピューティクス インコーポレイテッド |
薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
|
CA3069469A1
(en)
|
2017-07-21 |
2019-01-24 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
US12235261B2
(en)
|
2017-10-20 |
2025-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring cellular uptake of molecules
|
|
KR102831164B1
(ko)
|
2017-10-30 |
2025-07-07 |
에프. 호프만-라 로슈 아게 |
단일특이적 항체로부터 다중특이적 항체의 생체내 생성 방법
|
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
|
CA3079129C
(en)
|
2017-11-01 |
2023-02-28 |
F. Hoffmann-La Roche Ag |
Trifab-contorsbody
|
|
CN111511370A
(zh)
|
2017-11-01 |
2020-08-07 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
|
|
ES2984919T3
(es)
|
2017-11-06 |
2024-10-31 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
CN111556895B
(zh)
|
2017-11-14 |
2024-09-13 |
中外制药株式会社 |
抗-c1s抗体及使用方法
|
|
EP3720448A4
(en)
|
2017-12-06 |
2021-11-03 |
Avidity Biosciences, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
|
|
TWI817974B
(zh)
|
2017-12-28 |
2023-10-11 |
日商中外製藥股份有限公司 |
細胞毒性誘導治療劑
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
KR20200135313A
(ko)
|
2018-02-26 |
2020-12-02 |
제넨테크, 인크. |
항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
CN113840832A
(zh)
|
2018-05-14 |
2021-12-24 |
狼人治疗公司 |
可活化白介素-2多肽及其使用方法
|
|
WO2019222294A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CA3101272A1
(en)
|
2018-05-24 |
2019-11-28 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
EP3835321A4
(en)
|
2018-08-10 |
2022-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
|
|
TWI841595B
(zh)
|
2018-09-10 |
2024-05-11 |
大陸商南京傳奇生物科技有限公司 |
針對ｃｄ３３之單域抗體及其構築體
|
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
MX2021004774A
(es)
|
2018-10-29 |
2021-08-24 |
Hoffmann La Roche |
Formulacion de anticuerpos.
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
AR117453A1
(es)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
Fc de anticuerpos modificados y métodos para utilizarlas
|
|
EP4406555A3
(en)
|
2018-12-21 |
2024-11-06 |
Novartis AG |
Antibodies to pmel17 and conjugates thereof
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
BR112021012631A2
(pt)
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
WO2020154405A2
(en)
|
2019-01-22 |
2020-07-30 |
Genentech, Inc. |
Immunoglobulin a antibodies and methods of production and use
|
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
|
MX2021009087A
(es)
|
2019-01-29 |
2021-09-08 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
|
|
CN114026122B
(zh)
|
2019-02-21 |
2024-12-31 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
|
EP3938403A1
(en)
|
2019-03-14 |
2022-01-19 |
F. Hoffmann-La Roche AG |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
|
CN113795264A
(zh)
|
2019-03-19 |
2021-12-14 |
瓦尔希伯伦私人肿瘤研究基金会 |
采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
|
|
EP3956022A1
(en)
|
2019-04-19 |
2022-02-23 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
|
US12497615B2
(en)
|
2019-04-25 |
2025-12-16 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
SG11202112541RA
(en)
|
2019-05-14 |
2021-12-30 |
Werewolf Therapeutics Inc |
Separation moieties and methods and use thereof
|
|
AU2020309958A1
(en)
|
2019-07-10 |
2021-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
|
IL292458A
(en)
|
2019-11-06 |
2022-06-01 |
Genentech Inc |
Diagnostic and treatment methods for the treatment of hematological cancer
|
|
JP2023503258A
(ja)
|
2019-11-14 |
2023-01-27 |
ウェアウルフ セラピューティクス， インコーポレイテッド |
活性化可能サイトカインポリペプチド及びその使用方法
|
|
US20230192869A1
(en)
|
2019-12-06 |
2023-06-22 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
|
EP4072584B1
(en)
|
2019-12-13 |
2026-01-28 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
MY202559A
(en)
|
2019-12-27 |
2024-05-08 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibody and use thereof
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
CA3163833A1
(en)
|
2020-01-09 |
2021-07-15 |
Timothy B. Lowinger |
Site specific antibody-drug conjugates with peptide-containing linkers
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
PE20230252A1
(es)
|
2020-03-13 |
2023-02-07 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos de estos
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
KR20250074688A
(ko)
|
2020-03-19 |
2025-05-27 |
제넨테크, 인크. |
동종형 선택적 항-tgf-베타 항체 및 이용 방법
|
|
BR112022019137A2
(pt)
|
2020-03-27 |
2023-01-31 |
Avidity Biosciences Inc |
Composições e métodos de tratamento de distrofia muscular
|
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック， インコーポレイテッド |
がんに対する治療方法及び診断方法
|
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
AU2021293507A1
(en)
|
2020-06-18 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
|
|
CN116390772A
(zh)
|
2020-07-07 |
2023-07-04 |
博泰康医药公司 |
新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
|
|
CA3188000A1
(en)
|
2020-07-13 |
2022-01-20 |
Genentech, Inc. |
Cell-based methods for predicting polypeptide immunogenicity
|
|
EP4190801A4
(en)
|
2020-07-29 |
2024-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR MEASURING THE PHARMACOKINETICS OF A DRUG LABELED WITH A NON-RADIOACTIVE SUBSTANCE
|
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
CA3188426A1
(en)
|
2020-08-07 |
2022-02-10 |
Yichin Liu |
Flt3 ligand fusion proteins and methods of use
|
|
JP2023537683A
(ja)
|
2020-08-07 |
2023-09-05 |
ジェネンテック， インコーポレイテッド |
ポリペプチド免疫原性を予測するためのｔ細胞ベースの方法
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US12516118B2
(en)
|
2020-11-04 |
2026-01-06 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
CA3196539A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
MX2023006010A
(es)
|
2020-11-24 |
2023-06-08 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
|
|
JP2023553323A
(ja)
|
2020-11-25 |
2023-12-21 |
エクシリオ デベロップメント， インコーポレイテッド |
腫瘍特異的に切断可能なリンカー
|
|
CN116723861A
(zh)
|
2020-12-02 |
2023-09-08 |
上海复宏汉霖生物技术股份有限公司 |
抗GARP/TGFβ抗体及使用方法
|
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
|
KR20230137393A
(ko)
|
2021-01-28 |
2023-10-04 |
얀센 바이오테크 인코포레이티드 |
Psma 결합 단백질 및 이의 용도
|
|
JP2024508488A
(ja)
|
2021-03-01 |
2024-02-27 |
エクシリオ デベロップメント， インコーポレイテッド |
がんを治療するためのマスクされたｃｔｌａ４及びｐｄ１／ｐｄ－ｌ１抗体の組み合わせ
|
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
JPWO2022244838A1
(da)
|
2021-05-19 |
2022-11-24 |
|
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
AU2022297107B2
(en)
|
2021-06-25 |
2024-08-01 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
|
CR20240026A
(es)
|
2021-06-25 |
2024-03-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
MX2024002476A
(es)
|
2021-08-27 |
2024-05-20 |
Janssen Biotech Inc |
Anticuerpos anti-psma y usos de estos.
|
|
CA3231330A1
(en)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
JPWO2023058723A1
(da)
|
2021-10-08 |
2023-04-13 |
|
|
|
AU2021362997A1
(en)
|
2021-11-03 |
2024-05-16 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
IL312692A
(en)
|
2021-11-16 |
2024-07-01 |
Genentech Inc |
Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
|
|
JP2024547020A
(ja)
|
2021-12-17 |
2024-12-26 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｏｘ４０抗体、多重特異性抗体及びその使用方法
|
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
WO2023157989A1
(ko)
|
2022-02-17 |
2023-08-24 |
주식회사 노벨티노빌리티 |
항체-약물 접합체
|
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
CN118974096A
(zh)
|
2022-03-25 |
2024-11-15 |
上海复宏汉霖生物技术股份有限公司 |
抗msln抗体及使用方法
|
|
IL315770A
(en)
|
2022-04-01 |
2024-11-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
CN119013300A
(zh)
|
2022-04-13 |
2024-11-22 |
豪夫迈·罗氏有限公司 |
抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
|
|
AR129062A1
(es)
|
2022-04-13 |
2024-07-10 |
Genentech Inc |
Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
|
|
WO2023215293A1
(en)
|
2022-05-02 |
2023-11-09 |
Athanor Biosciences, Inc. |
Cancer eradicating – bio-nanoparticles (ce-bnp)
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
JP2025523020A
(ja)
|
2022-07-13 |
2025-07-17 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
EP4554624A1
(en)
|
2022-07-15 |
2025-05-21 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
|
IL318252A
(en)
|
2022-07-19 |
2025-03-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
AR129995A1
(es)
|
2022-07-22 |
2024-10-23 |
Genentech Inc |
Moléculas de unión al antígeno anti-steap1 y sus usos
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
KR20250089547A
(ko)
|
2022-10-25 |
2025-06-18 |
펩토믹, 에스.엘. |
암 치료를 위한 조합 요법
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
AR131320A1
(es)
|
2022-12-13 |
2025-03-05 |
Juno Therapeutics Inc |
Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
|
|
TW202448949A
(zh)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
WO2024251854A1
(en)
|
2023-06-07 |
2024-12-12 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with braf inhibitors for the treatment of cancer
|
|
TW202513088A
(zh)
|
2023-06-07 |
2025-04-01 |
瓦爾希伯倫私人腫瘤研究基金會 |
用於治療癌症的與ｍｅｋ抑制劑的組合療法
|
|
EP4473974A1
(en)
|
2023-06-07 |
2024-12-11 |
Peptomyc, S.L. |
Omomyc and kras inhibitors combination therapy for the treatment of cancer
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|